Antimicrobial resistance is a growing health crisis that could lead to millions of deaths by 2050, according to the World ...

Research into developing new antimicrobial resistance treatments in Nigeria and other low/middle-income countries has secured ...

The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...

Imagine one of Denmark's many picturesque beaches, the waves lapping against the shore, the golden sand and the smooth ...

Oysters contain an antimicrobial protein in their liquid similar to blood, according to a new study published in the journal ...

Pseudomonas bacteria infected by different mutations of a jumbo phage. The dot in the middle is the shield created by the ...

Photodynamic inactivation using curcumin shows promise in reducing antibiotic resistance diversity in Staphylococcus aureus, ...

Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...

Antibiotics are often thought of as an easy cure to bacterial infections, but they could be fueling an urgent public health ...

It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.

Diarrheagenic E. coli (DEC) is a major global cause of diarrheal diseases, with certain strains showing alarming levels of antibiotic resistance.

Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.